AI Article Synopsis
- Arterial hypertension (HTN) is a major cardiovascular risk factor, and while various treatments exist, resistant HTN remains challenging; biomarkers may play a role in understanding this condition.
- This study measured serum SDC4 levels in patients with resistant HTN before and after baroreflex activation therapy (BAT), analyzing samples from 19 individuals.
- Results indicated that SDC4 levels were significantly higher in resistant HTN patients, especially those with diabetes, with β-blockers reducing levels, while BAT didn't show notable changes after 6 months; SDC4 could be a potential marker for endothelial dysfunction in resistant HTN.
Article Abstract
(1) Background: Arterial hypertension (HTN) is one of the most relevant cardiovascular risk factors. Nowadays multiple pharmaceutical treatment options exist with novel interventional methods (e.g., baroreflex activation therapy (BAT)) as a last resort to treat patients with resistant HTN. Although pathophysiology behind resistant HTN is still not fully understood. There is evidence that selected biomarkers may be involved in the pathophysiology of HTN. (2) Methods: We investigated serum SDC4-levels in patients suffering from resistant HTN before and 6 months after BAT implantation. We collected 19 blood samples from patients with resistant HTN and blood pressure above target and measured serum SDC4-levels. (3) Results: Our results showed high serum SDC4-levels in patients with resistant HTN as compared to a healthy population. Patients with both, resistant HTN and diabetes mellitus type II, demonstrated higher serum SDC4-levels. β-blockers had lowering effects on serum SDC4-levels, whereas calcium channel blockers were associated with higher levels of serum SDC4. BAT implantation did not lead to a significant difference in serum SDC4-levels after 6 months of therapy. (4) Conclusion: Based on our results we propose SDC4 is elevated in patients suffering from resistant HTN. Thus, SDC4 might be a potential marker for endothelial dysfunction in patients with resistant hypertension.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564403 | PMC |
| http://dx.doi.org/10.3390/jcm9093051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical Histories Associated With Absence of Alzheimer Disease Neuropathologic Changes in the Oldest-Old: The 90+ Study.
Neurology
January 2025
From the Departments of Neurology (S.L., R.R., A.P.-H., M.M.C., C.K.) and Epidemiology and Biostatistics (M.M.C.), and the Institute for Memory Impairments and Neurological Disorders (Z.A.-D., M.M.C., C.K.), University of California, Irvine; Department of Epidemiology and Biostatistics, Temple University College of Public Health, Philadelphia, PA; and Pathology (T.J.M.), Stanford University, CA.
Objectives: Exploration of medical histories and medications associated with Alzheimer disease neuropathologic change (ADNC) absence and potential resistance may identify protective factors against ADNC. This was a retrospective examination of data from participants age ≥90 years who enrolled in , a longitudinal study based in California. Participants underwent neuropathologic analysis for the presence of neuritic amyloid plaques (NPs) (any), beta amyloid plaques (Thal phase > 0), and neurofibrillary tangles (>2).
View Article and Find Full Text PDFStudy of the association of markers of central and peripheral arterial stiffness with renal function in patients with arterial hypertension, diabetes mellitus and chronic kidney disease.
Nefrologia (Engl Ed)
December 2024
Unidad de Factores de Riesgo Vascular, Hospital Universitario, Jerez de la Frontera, Cádiz, Spain. Electronic address:
Rationale And Objectives: Increased aortic or central arterial stiffness (CAS) is a major factor in cardiovascular morbidity and mortality in patients with vascular risk factors. Decreased glomerular filtration rate (GFR) and increased urinary albumin excretion (uALB) are associated with lethal and non-lethal cardiovas-cular events. The pathophysiological mechanisms of this association are not fully defined.
View Article and Find Full Text PDFDetection of bla, bla, bla, and bla genes of antibiotic resistance in diarrheagenic E. coli causing enteric infection in hypertensive patients at Laquintinie Hospital, Littoral Region of Cameroon.
J Infect Public Health
December 2024
Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon. Electronic address:
Article Synopsis
- Pathogenic Escherichia coli is a leading cause of diarrhea globally, and this study investigates how virulence genes and antibiotic resistance differ in hypertensive versus non-hypertensive patients.* -
- Researchers analyzed 518 fecal samples from patients in Douala, discovering that certain strains like enteropathogenic E. coli (EPEC) were more common in hypertensive individuals, while enteroaggregative E. coli (EAEC) predominated in non-hypertensives.* -
- The study found high resistance rates of E. coli to antibiotics, especially amoxicillin and sulfamethoxazole-trimethoprim, with a significant prevalence of extended-spectrum β-lactamase-producing strains (
Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
Eur J Pharmacol
December 2024
Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; First Department of Internal Medicine, Cardiology, Olomouc University Hospital and Palacký University, Olomouc, Czech Republic.
Nitric oxide (NO)-stimulated cyclic guanosine monophosphate (cGMP) is a key regulator of cardiovascular health, as NO-cGMP signalling is impaired in diseases like pulmonary hypertension, heart failure and chronic kidney disease. The development of NO-independent sGC stimulators and activators provide a novel therapeutic option to restore altered NO signalling. sGC stimulators have been already approved for the treatment of pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and chronic heart failure (HFrEF), while sGC activators are currently in phase-2 clinical trials for CKD.
View Article and Find Full Text PDFTreatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.
Eur Urol Open Sci
January 2025
Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Background And Objective: Hypertension (HTN) has been linked to an elevated risk of prostate cancer (PC) development and poorer prognosis in localized cases, and is a common side effect of hormonal PC treatments. However, its relationship with the prognosis of metastatic PC is still unclear. We assessed the prognostic role of treatment-related HTN in patients with de novo metastatic hormone-sensitive PC (mHSPC) undergoing androgen deprivation therapy (ADT) alone or in combination with docetaxel or androgen receptor pathway inhibitors (ARPIs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!